Boston Scientific launches Infinion 16 percutaneous lead in EU

Boston Scientific has announced the European launch of its new Infinion 16 percutaneous lead for the Precision Plus spinal cord stimulator (SCS) system.

The new lead is being rolled out across Europe after receiving CE Mark approval, with the first EU patient implant using the new product having taken place in Sweden.

It is the world's first and only 16-contact percutaneous lead and helps to improve the functionality of Precision Plus, an innovative rechargeable SCS device for chronic pain management.

Using the device, clinicians can place 16 contacts with a single lead using a small insertion needle, while it also offers a high standard of responsiveness and excellent steering.

Maulik Nanavaty, Boston Scientific's senior vice-president and president of its neuromodulation division, said: "We believe that the European launch of the Infinion 16 Lead, coupled with increased awareness of pain management treatment alternatives, will allow us reach a wider patient population."

This month, the company also announced its 2011 financial results, reporting annual sales of $7.62 billion (4.82 billion pounds).